98 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
ARRY Array BioPharma Inc. $16.98 $3.53B Uptrend
Article Searches
ARRY: Stifel reits Buy http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180122072505 Jan 22, 2018 - Stifel issues rating change for ARRY
Array BioPharma (ARRY) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow https://seekingalpha.com/article/4136343-array-biopharma-arry-presents-36th-annual-j-p-morgan-healthcare-conference-slideshow?source=feed_all_articles Jan 09, 2018 - The following slide deck was published by Array BioPharma Inc. in conjunction with this event.
Week In Review: China Life Science Starts 2018 With $2 Billion Week https://seekingalpha.com/article/4135761-week-review-china-life-science-starts-2018-2-billion-week?source=feed_all_articles Jan 07, 2018 - Deals and Financings Perennial Real Estate Holdings (SGX: 40S), a Singapore company, announced a $1.2 billion joint venture that will acquire and develop healthcare centers in China. It plans to conce
Your Daily Pharma Scoop: Ardelyx Reports Data, Omeros Moves Forward With OMS721, Allergan Announces Job Cuts https://seekingalpha.com/article/4135192-daily-pharma-scoop-ardelyx-reports-data-omeros-moves-forward-oms721-allergan-announces-job?source=feed_sector_healthcare Jan 04, 2018 - Ardelyx announced a significant drop in diarrhea incidence. Omeros reached an agreement with FDA on design of Phase 3 trial for OMS 721 in IgN. Allergan announced that it will cut more than 1,000 jobs
ROTY Edition 1 Volume 66: GW Pharmaceuticals Gets Closer To The Finish Line - And Other Updates https://seekingalpha.com/article/4134311-roty-edition-1-volume-66-gw-pharmaceuticals-gets-closer-finish-line-updates?source=feed_all_articles Dec 28, 2017 - December performance is picking up significantly.ROTY has gotten off to a great start and much of that is due to support from readers. In coming months the discussion will shift to future formats and
Array BioPharma spins off cardiovascular myopathy drug research into new subisidiary http://feeds.bizjournals.com/~r/industry_6/~3/1ITe_UPY6yY/array-biopharma-spins-off-cardiovascular-myopathy.html Dec 26, 2017 - Boulder drug development company Array BioPharma has spun off its research into a treatment for a rare degenerative heart disease into a separate company. Array BioPharma (Nasdaq: ARRAY), in a filing to the U.S. Securities & Exchange Commission on Chistmas Eve, revealed that it had contributed intellectual property, inventory, equipment, clinical trial data and other material about its experimental cardiomyopathy drug to a subsidiary it’s calling Yarra Therapeutics. The oral drug, known only…
Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL https://seekingalpha.com/article/4133858-daily-pharma-scoop-amgen-plans-bring-back-cash-roche-acquires-ignyta-agile-tumbles-crl?source=feed_sector_healthcare Dec 26, 2017 - Amgen plans to repatriate some of its cash holdings kept outside the U.S. Roche acquired Ignyta, paying premium of more than 70%. Agile tumbled nearly 50% on CRL.
Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session http://www.zacks.com/stock/news/286918/array-biopharma-arry-looks-good-stock-adds-96-in-session?cid=CS-ZC--286918 Dec 26, 2017 - Array BioPharma (ARRY) shares rose nearly 10% in the last trading session, amid huge volumes.
ROTY Edition 1 Volume 65: My Recent Interview And Promising Updates On Holdings https://seekingalpha.com/article/4133344-roty-edition-1-volume-65-recent-interview-promising-updates-holdings?source=feed_tag_etf_portfolio_strategy Dec 21, 2017 - I remind readers to check out  my recent interview with Seeking Alpha Editor Steve Brown for my thoughts on the year ahead and themes that could work.Perceptive Advisors' stake in Global Blood Therape
Your Daily Pharma Scoop: Valeant Still Risky, Onconova Signs Agreement, Array Biopharma Announces Collaboration https://seekingalpha.com/article/4132915-daily-pharma-scoop-valeant-still-risky-onconova-signs-agreement-array-biopharma-announces?source=feed_sector_healthcare Dec 20, 2017 - Despite the gains this year, Valeant still remains a risky bet.Onconova has signed an agreement with HanX of China.Array Biopharma announced collaboration with Pfizer.

Pages: 12345678...10

<<<Page 3>